Recent News

• 02.27.2025 - Alpha Tau to Participate in March Investor Conferences
• 02.24.2025 - Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
• 02.03.2025 - Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
• 01.27.2025 - Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
• 01.27.2025 - Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
• 12.18.2024 - Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
• 12.17.2024 - Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
• 12.17.2024 - Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Recent Filings

• 02.27.2025 - EX-99.1 EX-99.1
• 02.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.24.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.24.2025 - EX-99.1 EX-99.1
• 02.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.03.2025 - EX-99.1 EX-99.1
• 01.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.27.2025 - EX-99.1 EX-99.1
• 12.18.2024 - EX-99.1 EX-99.1
• 12.18.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]